Trelegy (fluticasone furoate+umeclidinium+vilanterol), which has been developed with partner Innoviva, is a three-in-one inhaler that is a successor to GSK’s two-in-one inhaler Advair.

Fluticasone furoate, umeclidinium, vilanterol 100/62.5/25mcg, 200/62.5/25mcg; per inh; dry pwd for oral inhalation. Trelegy Ellipta is supplied as a disposable light grey and beige plastic inhaler ...

Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) is a brand-name inhaler that’s prescribed for COPD. This article covers topics such as side effects, dosage ...

The FDA has approved an expanded label for GlaxoSmithKline’s new Trelegy Ellipta inhaler, allowing it to be used in a broader population of patients with chronic obstructive pulmonary disease ...

Meanwhile GSK's lead inhalers include Trelegy Ellipta, projected to bring $3.3bn in 2024 sales, followed by Relvar/Breo Ellipta and Seretide/Advair GlobalData is the patent company of Pharmaceutical ...